Qualigen Therapeutics Inc (QLGN): Price and Financial Metrics
QLGN Price/Volume Stats
| Current price | $1.03 | 52-week high | $6.50 |
| Prev. close | $1.07 | 52-week low | $0.83 |
| Day low | $1.03 | Volume | 36,900 |
| Day high | $1.10 | Avg. volume | 238,992 |
| 50-day MA | $0.96 | Dividend yield | N/A |
| 200-day MA | $1.72 | Market Cap | 5.20M |
QLGN Stock Price Chart Interactive Chart >
QLGN Stock Summary
- QLGN has a market capitalization of $4,799,840 -- more than approximately only 1.58% of US stocks.
- The volatility of QUALIGEN THERAPEUTICS INC's share price is greater than that of 94.02% US stocks with at least 200 days of trading history.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for QLGN comes in at -60.49% -- higher than that of only 8.88% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to QUALIGEN THERAPEUTICS INC are UPST, ROIV, HLGN, RAMP, and RELY.
- Visit QLGN's SEC page to see the company's official filings. To visit the company's web site, go to www.qualigeninc.com.
QLGN Valuation Summary
- QLGN's price/sales ratio is 0.8; this is 63.64% lower than that of the median Healthcare stock.
- Over the past 96 months, QLGN's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for QLGN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| QLGN | 2023-05-23 | 0.8 | 1 | -0.3 | -0.2 |
| QLGN | 2023-05-22 | 0.9 | 1 | -0.3 | -0.2 |
| QLGN | 2023-05-19 | 0.9 | 1 | -0.3 | -0.2 |
| QLGN | 2023-05-18 | 0.8 | 1 | -0.3 | -0.2 |
| QLGN | 2023-05-17 | 0.8 | 1 | -0.3 | -0.2 |
| QLGN | 2023-05-16 | 0.9 | 1 | -0.3 | -0.2 |
QLGN Growth Metrics
- The 5 year cash and equivalents growth rate now stands at 16.9%.
- Its 4 year cash and equivalents growth rate is now at 16.9%.
- Its 4 year net cashflow from operations growth rate is now at 40.82%.
The table below shows QLGN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 5.074857 | -13.92315 | -18.32906 |
| 2022-06-30 | 4.788857 | -13.77348 | -17.36247 |
| 2022-03-31 | 4.476258 | -16.53125 | -18.5443 |
| 2021-12-31 | 5.653725 | -14.73074 | -17.89714 |
| 2021-09-30 | 5.280276 | -15.27428 | -4.690626 |
| 2021-06-30 | 4.962925 | -16.7582 | -9.945321 |
QLGN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- QLGN has a Quality Grade of C, ranking ahead of 42.69% of graded US stocks.
- QLGN's asset turnover comes in at 0.208 -- ranking 197th of 681 Pharmaceutical Products stocks.
- XBIT, AYTU, and QDEL are the stocks whose asset turnover ratios are most correlated with QLGN.
The table below shows QLGN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.208 | 0.204 | 1.367 |
| 2021-03-31 | 0.226 | 0.191 | 2.289 |
| 2020-12-31 | 0.350 | 0.187 | 2.195 |
| 2020-09-30 | 0.179 | 0.007 | 3.635 |
| 2020-06-30 | 0.172 | 0.106 | 5.369 |
| 2020-03-31 | 0.000 | NA | 5.491 |
QLGN Price Target
For more insight on analysts targets of QLGN, see our QLGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $9.75 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Qualigen Therapeutics Inc (QLGN) Company Bio
Qualigen Therapeutics Inc operates as a biotech company. The Company develops and discovers novel therapeutic products for the treatment of cancer and infectious diseases. Qualigen Therapeutics serves customers in the State of California.
Latest QLGN News From Around the Web
Below are the latest news stories about QUALIGEN THERAPEUTICS INC that investors may wish to consider to help them evaluate QLGN as an investment opportunity.
Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingQualigen Therapeutics, Inc. Co-operation between RAS-F series and AMG-510 and MRTX1133 Preclinical Data Show Potential to Overcome Resistance to Key KRAS-G12C Therapeutic Compounds CARLSBAD, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces today that a poster featurin |
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023Company Reports 123% Increase in Year-Over-Year Revenue CARLSBAD, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces financial results for the first quarter ending March 31, 2023, and provides a corporate update. Highlights For First Quarter and To Date 2023: Thera |
QLGN: IND for QN-302 to be Submitted in Mid-2023…By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update IND to be Filed for QN-302 in Mid-2023 Qualigen Therapeutics, Inc. (NASDAQ:QLGN) is continuing work toward the submission of an Investigational New Drug (IND) application for its lead therapeutic program, QN-302. We anticipate an IND being filed for QN-302 in mid-2023. QN-302 is a G-quadruplex (G4)-selective |
Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate UpdateCARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics, Inc.), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces financial results for the fourth quarter and fiscal year ended December 31, 2022, and provides an update on the company’s therapeutics pipeline and other corporate developments |
Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingAbstracts Feature Preclinical Data in (1) Pancreatic Cancer and (2) Luminal B Breast Cancer CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces that two abstracts featuring the Company’s pan-RAS inhibitor program will be included in the American Society of Clini |
QLGN Price Returns
| 1-mo | -4.62% |
| 3-mo | -4.63% |
| 6-mo | -30.41% |
| 1-year | -82.83% |
| 3-year | -98.25% |
| 5-year | -99.87% |
| YTD | -20.09% |
| 2022 | -87.95% |
| 2021 | -64.45% |
| 2020 | -28.72% |
| 2019 | -71.85% |
| 2018 | -81.82% |
Loading social stream, please wait...